We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Multiplex PCR Platform Detects 21 Common Respiratory Organisms

By LabMedica International staff writers
Posted on 01 Feb 2010
A user-friendly multiplex polymerase chain reaction (PCR) platform is capable of detecting 21 common respiratory viruses and bacteria.

The FilmArray is simplified molecular testing; easy-to-use, the massive multiplex PCR turns a sample into results in less than 1 hour. More...
It requires only 5 minutes of hands-on time.

A product of Idaho Technology (ITI; Salt Lake City, UT, USA), the FilmArray integrates sample preparation, amplification, detection, and analysis into one system that is fully automated and is capable of rapidly detecting more than 100 targets in one sample.

Clinical trials of the FilmArray RP will be conducted at the Children's Medical Center (Dallas, TX, USA) in association with University of Texas (UT) Southwestern Medical Center, (Dallas, TX, USA); the Detroit Medical Center, (Detroit, MI, USA); and the Medical University of South Carolina (Charleston, SC, USA).

Nasopharyngeal swab specimens from 1,000 patients will be tested using the FilmArray RP and compared to results from conventional as well as other molecular diagnostic technologies. If that the trials are successful, the company will submit a 510k application to the US Food and Drug Administration (FDA; Silver Spring, MD, USA) for use of the FilmArray RP as an in vitro diagnostic (IVD) product for patients with symptoms of upper respiratory tract infection.

Kirk Ririe, CEO of Idaho Technology said, "The FilmArray RP is a powerful molecular diagnostic assay designed for comprehensive detection of common respiratory pathogens, and yet is still incredibly simple and easy to use," said Kirk Ririe, CEO of Idaho Technology.

Idaho Technology, Inc. licensed the rapid PCR technology from the University of Utah (Salt Lake City, UT, USA). The company has created many commercial instruments and reagents for use in applied and research fields. Several of these products, including the LightCycler Instrument, have been sublicensed to Roche Diagnostics (Basel, Switzerland). Laboratory personnel, researchers, law enforcement officers, and soldiers in the field use the company's devices to detect or study disease-causing organisms.

Related Links:

Idaho Technology
Children's Medical Center
UT Southwestern Medical Center
Detroit Medical Center
Medical University of South Carolina
US Food and Drug Administration
Roche Diagnostics



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.